drugset / Trial / NCT01027416

Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients

NCT01027416

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will help to understand the interaction between estrogen receptor-alpha (ER alpha) and tumor suppressor protein p53 as well as impact on patient tumor gene expression in response to the hormonal therapy Tamoxifen. This information may eventually help select the appropriate therapy for future patients with similar cancer.

Timeline

Start
2009-12-14
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tamoxifen Small molecule 20 mg Oral

Indications